All In Biotech

Free tool

FAERS Monitor: Hycodan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 005213 or its brand name (Hycodan, Homatropine Methylbromide, Hydrocodone Bitartrate). Reports on generic versions are filed under their own applications.

Reports

32

Serious

10

31% of reports

Hospitalization

1

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • abdominal pain upper3
  • constipation3
  • decreased appetite3
  • hypersensitivity3
  • injection site rash3
  • nausea3
  • adverse drug reaction2
  • chronic kidney disease2
  • diarrhoea2
  • dizziness2
  • pain2
  • somnolence2
  • vomiting2
  • ageusia1
  • ataxia1

Reports by year received

View as table
YearReports
20081
20101
20141
20183
20193
202010
20214
20221
20231
20241
20251
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,127 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
injection site rashSignal364.321.9129
ataxia155.48.013
ageusia126.43.86
chronic kidney disease217.34.517
adverse drug reaction214.63.814
hypersensitivitySignal310.63.618
abdominal pain upperSignal39.63.315
constipationSignal39.03.114
decreased appetiteSignal38.52.913
somnolence26.51.75
vomiting22.80.71
dizziness22.60.71
nausea32.50.81
pain22.10.60
diarrhoea22.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.